DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for lupus erythematosus — screening already-approved drugs against its 11-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLupus erythematosus maps to a 11-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lupus erythematosus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase non-receptor type 2 (PTPN2) — PTPN2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5pdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8U0H · 1.93 Å · ligand (5P)-3-(carboxymethoxy)-4-chloro-5-(3-{[(4S)-1-({3-[2-(4-{3-[(3R)-2,6-dioxopiperidin-3-yl]-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl}piperidin-1-yl)acetamido]phenyl}methanesulfonyl)-2,2-dimethylpiperidin-4-yl]amino}phenyl)thiophene-2-carboxylic acid (UB0). Experimental structure, not a prediction.
What the evidence adds up to
Systemic lupus erythematosus is a chronic autoimmune disease in which nuclear components of cells become the main targets of the immune reaction, potentially affecting any organ. It is considered a prototype disease because its clinical symptoms substantially overlap with other autoimmune conditions. Both genetic factors, such as mutations or susceptibility alleles, and environmental triggers including infections, drugs, stress, and exposures contribute to its development. Research from 2004 highlighted two promising pathways in the genetics of SLE: the PD-1 pathway and the interferon pathway.
A retrospective observational study from 2014 examined patients with SLE refractory to conventional treatment who received rituximab for remission induction and maintenance. The study reported a significant reduction in the dose of conventional immunosuppressive drugs and a decrease in the number of disease relapses. The authors stated that rituximab appeared effective and safe for induction and maintenance of remission in this refractory patient group. No specific numbers for response rates, survival, or sample size were provided in the abstract.
A 2019–2020 update noted that scientific understanding of SLE pathogenesis has undergone a paradigm shift, and diagnostic criteria continue to be modified as clinical experience accumulates. The same update stated plainly that treatment of SLE still leaves a lot to be desired, though new additions and alterations to management occur each year.
What remains missing is large-scale, randomised controlled trial data for rituximab in refractory SLE, as the available evidence is from a small retrospective study without a comparator group. The genetic pathways identified in 2004 have not yet translated into widely available targeted therapies. No trial design has definitively stratified patients by genetic or biomarker profiles to predict which individuals might benefit from specific treatments.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Molecular Genetics · 2004 · 56 citations
The genetic basis of systemic lupus erythematosus--knowledge of today and thoughts for tomorrow
AbstractSystemic lupus erythematosus (SLE) is a chronic rheumatic disease with an autoimmune etiology. Nuclear components of the cells are the main targets of the autoimmune reaction, affecting virtually any organ in the body. SLE is also called a prototype disease due to a substantial overlap in its clinical symptoms with other autoimmune diseases. Therefore the understanding of the mechanisms underlying SLE may contribute to advances in studies and development of new treatments for several autoimmune diseases. SLE is a complex disease with both genetic factors (mutations or susceptibility alleles) and environmental factors (infections, drugs, stress, exposures, etc.) contributing to its development. In this article we will give an overview of the latest findings in genetics of SLE, concentrating on the two most interesting and promising pathways: the PD-1 and the interferon pathways.
Autoimmune Diseases · 2014 · 23 citations · open access
Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
AbstractSystemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.
Anticancer Research · 2019 · 16 citations · open access
Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review
AbstractBACKGROUND: Various immune-related adverse events (irAEs) have been reported to be associated with the use of immune checkpoint inhibitors. We report a case of a patient with lung cancer treated with nivolumab who developed a bullous eruption and give a systematic review of the literature on irAEs in patients treated with immune checkpoint inhibitors for lung cancer. CASE REPORT: A patient with lung adenocarcinoma developed a non-specific skin lesion at the time of his cancer diagnosis followed by flare episodes until the eighth cycle of nivolumab, when he developed a bullous lupus. As the first eruption had started a few months after his cancer diagnosis and was exacerbated during immunotherapy, a paraneoplastic origin is discussed. Since the patient also presented with flares under nivolumab, we reviewed reported irAEs. No bullous lupus was found but to date, 33 cases of paraneoplastic lupus and two of lupus erythematosus have been reported. CONCLUSION: To our knowledge, this is the first description of a bullous lupus exacerbated by nivolumab.
What is New in Systemic Lupus Erythematosus: A 2019–2020 Update
AbstractScientific understanding of systemic lupus erythematosus (SLE) is progressing at a steady pace. Thus, there has been a paradigm shift in the understanding of the pathogenesis of SLE. As clinical experience of SLE is accumulating, the criteria for diagnosis are also being modified. Treatment of SLE still leaves a lot to be desired but every year, there are new additions and alterations. This article sums up these recent changes, especially those in the management of SLE.
Greater South Information System · 2014 · 0 citations · open access
Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
AbstractSystemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
